Our website is made possible by displaying non-intrusive online advertisements to our visitors.
Please consider supporting us by disabling or pausing your ad blocker.
this been R&D more than 20 years want to know more knowledge can visit thier website . Life sciene will be major contribution with 55million People living with dementia
Say goodbye to IR business $1.3 trillion Estimated global cost of dementia help global save 90% money =130billion USD or 99% Money = 13billion USD convert to MYR yourself will be very scary figure
trial is finish now is pending regulator approve only thier factory is already standby manufacture the drug once approve and get in to market you need do more homework who is thier manufacturer
The Phase 3 trial for Genting's Alzheimer’s drug, conducted by their associate company TauRx, is now completed, and the drug is awaiting regulatory approval. TauRx is working with authorities in both the United States and the United Kingdom to clear the drug, which is known as hydromethylthionine mesylate (HMTM). This drug, designed to slow cognitive decline in Alzheimer's patients, has demonstrated favorable safety profiles and cost advantages, as it is orally administered compared to many competitors that require intravenous delivery.
Currently, TauRx has a manufacturing facility on standby, prepared to begin production as soon as approval is granted. This readiness emphasizes the company's focus on quickly bringing the drug to market once regulatory clearance is obtained, which could provide Genting with significant returns if the approval process is successful.
The manufacturer ready to produce TauRx’s Alzheimer's drug, hydromethylthionine mesylate (HMTM), after regulatory approval appears to be part of TauRx’s own advanced preparation efforts, though specific details about a third-party manufacturer are not fully disclosed. TauRx has filed for regulatory approval in the UK and is planning to release HMTM for mild to moderate Alzheimer’s stages, with expectations for rapid production and market entry upon approval.
The drug targets tau protein buildup and aims to slow disease progression, which TauRx claims will be a breakthrough if approved. As the regulatory review progresses, TauRx is likely managing its production through its in-house or partnered facilities, though further information about the exact manufacturing partner may be released once approvals are secured.
if 55million patient x 1000USD enough every year taking to stop become worst it could be 55 billion USD compare to peer 26k USD it help reduce more than 90% cost